ReviewEBioMedicine2019
Glucose and glycogen in the diabetic kidney: Heroes or villains?
Review in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 80 citations in OpenAlex.
- Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects.Diabetes · 2024Trial
- Molecular mechanisms and novel therapeutic targets of diabetic kidney disease.Chinese medical journal · 2026Review
- Urinary microenvironment-degradable nanocapsules for traceable therapy of diabetic nephropathy.Materials today. Bio · 2026Article
- Evaluation of the Role of Taurine in Mitigating the Deleterious Effects of Tartrazine on the Kidneys in Rats: Experimental Study.Turk patoloji dergisi · 2026Article
- Transcriptome-wide association study revealed novel causal genes of renal-biopsy proven diabetic nephropathy.Genome medicine · 2025Article
- Interleukin-6 modulates endoplasmic reticulum stress signaling and mitochondrial protein complexes in the kidney following acute exhaustive exercise.Cell stress & chaperones · 2025Article
- Human glycogenins maintain glucose homeostasis by regulating glycogen metabolism.Nature communications · 2025Article
- Asiatic Acid Alleviates Renal Damage by Upregulating STBD1-Mediated Glycophagy in Diabetic Kidney Disease.Biomedicines · 2025Article
- Clinical Impact of Glucose Levels on Patient Outcome after Transcatheter Aortic Valve Replacement.Reviews in cardiovascular medicine · 2025Article
- Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy.Frontiers in immunology · 2025Review
- Tubular glycogen accumulation in acute kidney injury associated with red yeast rice supplement.Clinical kidney journal · 2024Article
- Irisin promotes hair growth and hair cycle transition by activating the GSK-3β/β-catenin pathway.Experimental dermatology · 2024Article
- Article
- Tea seed saponin‑reduced extract ameliorates palmitic acid‑induced insulin resistance in HepG2 cells.Molecular medicine reports · 2024Article
- A fingerprint of 2-[iScience · 2023Article
- Analysis of Cell Glycogen with Quantitation and Determination of Branching Using Liquid Chromatography-Mass Spectrometry.Analytical chemistry · 2023Article
- Gluconeogenesis in the kidney: in health and in chronic kidney disease.Clinical kidney journal · 2023Review
- Deuterium body array for the simultaneous measurement of hepatic and renal glucose metabolism and gastric emptying with dynamic 3D deuterium metabolic imaging at 7 T.NMR in biomedicine · 2023Article
- Phloretamide Prevent Hepatic and Pancreatic Damage in Diabetic Male Rats by Modulating Nrf2 and NF-κB.Nutrients · 2023Article
- Nanoplastics Toxicity Specific to Liver in Inducing Metabolic Dysfunction-A Comprehensive Review.Genes · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose metabolism in the kidney is currently foremost in the minds of nephrologists, diabetologists and researchers globally, as a result of the outstanding success of SGLT2 inhibitors in reducing renal and cardiovascular disease in individuals with diabetes. However, these exciting data have come with the puzzling but fascinating paradigm that many of the beneficial effects on the kidney and cardiovascular system seem to be independent of the systemic glucose lowering actions of these agents. This manuscript places into context an area of research highly relevant to renal glucose metabolism, that of glycogen accumulation and metabolism in the diabetic kidney. Whether the glycogen that abnormally accumulates is pathological (the villain), is somehow protective (the hero) or is inconsequential (the bystander) is a research question that may provide insight into the link between diabetes and diabetic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.